← All trials

NCT04756154

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jul 6, 2020
Primary completion
May 15, 2021
Completion date
May 30, 2021
First posted
Feb 16, 2021
Last posted
Mar 1, 2021
Enrollment
135
Arms / groups
3 / —
Source
AACT · ingestion pipeline

Sponsors

  • 3MLead sponsor
  • MicrobacOverall official - principal investigator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.